Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders

Journal of Psychiatry and Neuroscience

Volumn 40, Issue 3, 2015, Pages 197-206

  Koenders, Laura ^a   Machielsen, Marise W J ^a   van der Meer, Floor J ^a   van Gasselt, Angelique C M ^a   Meijer, Carin J ^a   van den Brink, Wim ^a   Koeter, Maarten W J ^a   Caan, Matthan W A ^a   Cousijn, Janna ^a   den Braber, Anouk ^b   Van ‘T Ent, Dennis ^b   Rive, Maaike M ^a   Schene, Aart H ^a,d,e   de van Giessen, Elsmarieke ^a   Huyser, Chaim ^a,c   de Kwaasteniet, Bart P ^a   Veltman, Dick J ^a,b   de Haan, Lieuwe ^a  

^a Department of Psychiatry ^*  (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c De Bascule   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; NICOTINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRAIN SIZE; CANNABIS USE; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); DISEASE ASSOCIATION; DSM-IV; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PUTAMEN; SCHIZOPHRENIA; SCORING SYSTEM; TOBACCO DEPENDENCE; BRAIN; CANNABIS ADDICTION; COMPLICATION; DRUG EFFECTS; GRAY MATTER; ORGAN SIZE; PATHOLOGY; SMOKING; YOUNG ADULT;

ANTIPSYCHOTIC AGENTS; BRAIN; GRAY MATTER; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MARIJUANA ABUSE; ORGAN SIZE; SCHIZOPHRENIA; SMOKING; YOUNG ADULT;

EID: 84928736654     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.140081     Document Type: Article

References (60)

1. Caspari D. Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci 1999;249:45-9.
2. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994;51:273-9.
3. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-28.
4. Bersani G, Orlandi V, Kotzalidis GD, et al. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci 2002;252:86-92.
5. Bühler B, Hambrecht M, Loffler W, et al. Precipitation and determination of the onset and course of schizophrenia by substance abuse–a retrospective and prospective study of 232 populationbased first illness episodes. Schizophr Res 2002;54:243-51.
6. Dekker N, Meijer J, Koeter M, et al. GROUP Investigators. Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender. Psychol Med 2012;42:1903-11.
7. Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull 1990;16:31-56.
8. Shepherd AM, Laurens KR, Matheson SL, et al. Systematic metareview and quality assessment of the structural brain alterations in schizophrenia. Neurosci Biobehav Rev 2012;36:1342-56.
9. Sommer I, Ramsey N, Kahn R, et al. Handedness, language lateralisation and anatomical asymmetry in schizophrenia: metaanalysis. Br J Psychiatry 2001;178:344-51.
10. Malchow B, Hasan A, Fusar-Poli P, et al. Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. Eur Arch Psychiatry Clin Neurosci 2013;263:3-13.
11. James A, James C, Thwaites T. The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review. Psychiatry Res 2013; 214:181-9
12. James A, Hough M, James S, et al. Greater white and grey matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS). Schizophr Res 2011;128:91-7.
13. Szeszko PR, Robinson DG, Sevy S, et al. Anterior cingulate greymatter deficits and cannabis use in first-episode schizophrenia. Br J Psychiatry 2007;190:230-6.
14. Bangalore SS, Prasad KMR, Montrose DM, et al. Cannabis use and brain structural alterations in first episode schizophrenia — a region of interest, voxel based morphometric study. Schizophr Res 2008;99:1-6.
15. Rapp C, Walter A, Studerus E, et al. Cannabis use and brain structural alterations of the cingulate cortex in early psychosis. Psychiatry Res 2013;214:102-8.
16. Cahn W, Hulshoff Pol HE, Caspers E, et al. Cannabis and brain morphology in recent-onset schizophrenia. Schizophr Res 2004;67:305-7.
17. Wobrock T, Czesnik D, Malchow B. Schizophrenia and comorbid substance abuse. In: Pathophysiological and therapeutic approaches Ritsner MS, editor. Springer Netherlands; 2011; p. 321-63. Available: http​ ://dx.doi.org/10.1007/978-94-007-0834-1_15 (accessed 2014 Dec. 15).
18. Cohen M, Rasser PE, Peck G, et al. Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults. Int J Neuropsychopharmacol 2012;15:297-307.
19. Kumra S, Robinson P, Tambyraja R, et al. Parietal lobe volume deficits in adolescents with schizophrenia and adolescents with cannabis use disorders. J Am Acad Child Adolesc Psychiatry 2012; 51:171-80.
20. Haller S, Curtis L, Badan M, et al. Combined grey matter VBM and white matter TBSS analysis in young first episode psychosis patients with and without cannabis consumption. Brain Topogr 2013;26:641-7.
21. Schnell T, Kleiman A, Gouzoulis-Mayfrank E, et al. Increased gray matter density in patients with schizophrenia and cannabis use: a voxel-based morphometric study using DARTEL. Schizophr Res 2012; 138:183-7.
22. Arseneault L, Cannon M, Poulton R, et al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325:1212-3.
23. Cohen M, Solowij N, Carr V. Cannabis, cannabinoids and schizophrenia: integration of the evidence. Aust NZ J Psychiatry 2008;42:357-68.
24. Hall WD. Cannabis use and the mental health of young people. Aust NZ J Psychiatry 2006;40:105-13.
25. Malone DT, Hill MN, Rubino T. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol 2010;160:511-22.
26. Wilson W, Mathew R, Turkington T, et al. Brain morphological changes and early marijuana use. J Addict Dis 2000;19:1-22.
27. Cousijn J, Wiers RW, Ridderinkhof KR, et al. Grey matter alterations associated with cannabis use: results of a VBM study in heavy cannabis users and healthy controls. Neuroimage 2012;59:3845-51.
28. Battistella G, Fornari E, Annoni JM, et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology 2014;39:2041-48.
29. Lorenzetti V, Lubman DI, Whittle S, et al. Structural MRI findings in long-term cannabis users: what do we know? Subst Use Misuse 2010;45:1787-808.
30. Lorenzetti V, Solowij N, Fornito A, et al. The association between regular cannabis exposure and alterations of human brain morphology: an updated review of the literature. Curr Pharm Des 2014;20:2138-67.
31. Rakic P. Specification of cerebral cortical areas. Science 1988;241:170-6.
32. Rimol LM, Nesvag R, Hagler DJ Jr, et al. Cortical volume, surface area, and thickness in schizophrenia and bipolar disorder. Biol Psychiatry 2012;71:552-60.
33. Wierenga LM, Langen M, Oranje B, et al. Unique developmental trajectories of cortical thickness and surface area. Neuroimage 2014;87:120-6.
34. Raznahan A, Shaw P, Lalonde F, et al. How does your cortex grow? J Neurosci 2011;31:7174-7.
35. Rentería ME. Cerebral asymmetry: a quantitative, multifactorial, and plastic brain phenotype. Twin Research and Human Genetics. 2012;15:401-13.
36. Levitt JJ, Bobrow L, Lucia D, et al. A Selective Review of Volumetric and Morphometric Imaging in Schizophrenia In: Swerdlow NR, editor. Behavioral Neurobiology of Schizophrenia and Its Treatment. Springer Berlin Heidelberg; 2010; 243-81.
37. Solowij N, Walterfang M, Lubman DI, et al. Alteration to hippocampal shape in cannabis users with and without schizophrenia. Schizophr Res 2013;143:179-84.
38. Habets P, Marcelis M, Gronenschild E, et al. Genetic risk and outcome of psychosis (G.R.O.U.P). Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. Biol Psychiatry 2011;69:487-94.
39. Andreasen NC, Flaum M, Arndt S. The comprehensive assessment of symptoms and history (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992;49:615-23.
40. Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry 2010;22:417-28.
41. Shahand S, Santcroos M, van Kampen AHC, et al. A grid-enabled gateway for biomedical data analysis. J Grid Computing 2012;10:725-42.
42. Shahand S, Santcroos M, van Kampen AHC, et al. A grid-enabled gateway for biomedical data analysis. J Grid Computing 2012;10:725-42.
43. Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 1997;16:2529-42.
44. Li W, van Tol MJ, Li M, et al. Regional specificity of sex effects on subcortical volumes across the lifespan in healthy aging. Hum Brain Mapp 2014;35:238-47.
45. Haller S, Borgwardt SJ, Schindler C, et al. Can cortical thickness asymmetry analysis contribute to detection of at-risk mental state and first-episode psychosis? A pilot study. Radiology 2009;​250:212-21.
46. Wobrock T, Sittinger H, Behrendt B, et al. Comorbid substance abuse and brain morphology in recent-onset psychosis. Eur Arch Psychiatry Clin Neurosci 2009;259:28-36.
47. Potvin S, Mancini-Marïe A, Fahim C, et al. Increased striatal gray matter densities in patients with schizophrenia and substance use disorder: a voxel-based morphometry study. Psych Research 2007;154:275-9.
48. Meijer JH, Dekker N, Koeter MW, et al. Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. Psychol Med 2012;42:705-16.
49. Yücel M, Bora E, Lubman DI, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a metaanalysis of existing findings and new data in a first-episode sample. Schizophr Bull 2012;38:316-30.
50. Rais M, van Haren NEM, Cahn W, et al. Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. Eur Neuropsychopharmacol 2010;20:855-65.
51. González-Pinto A, Alberich S, Barbeito S, et al. Cannabis and firstepisode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull 2011;37:631-9.
52. Demirakca T, Sartorius A, Ende G, et al. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend 2011;141:242-5.
53. Malchow B, Hasan A, Schneider-Axmann T, et al. Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci 2013;263:155-68.
54. Everitt BJ, Robbins TW. From the ventral to the dorsal striatum: devolving views of their roles in drug addiction. Neurosci Biobehav Rev 2013;37:1946-54.
55. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 2005;8:1481-9.?
56. Fritz H, Wittfeld K, Schmidt CO, et al. Current smoking and reduced gray matter volume: a voxel-based morphometry study. Neuropsychopharmacology 2014;39:2594-600.
57. Schneider CE, White T, Hass J, et al. Smoking status as a potential confounder in the study of brain structure in schizophrenia. J Psychiatr Res 2014;3:84-91.
58. Tregellas JR, Shatti S, Tanabe JL, et al. Gray matter volume differences and the effects of smoking on gray matter in schizophrenia. Schizophr Res 2007;97:242-9.
59. Van Haren NEM, Koolschijn PCMP, Cahn W, et al. Cigarette smoking and progressive brain volume loss in schizophrenia. Eur Neuropsychopharmacol 2010;20:454-8.
60. Han X, Jovicich J, Salat D, et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage 2006;​ 32:180-94.